Oct 20,2022

Dario Announces Two Employer Contracts for Full Suite of Digital Health Solutions

DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced today the company's full suite of chronic condition management solutions were selected by two employers to help improve overall employee health beginning in the first quarter of 2023.

PRODUCT

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 02,2022

CureApp: Digital Therapeutic App for Hypertension Receives Insurance Coverage, Sales of the Service to Medical Institutions

CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake) announces the start of insurance coverage for its CureApp HT Hypertension Adjunctive Treatment App (hereafter, CureApp HT), a DTx^*1 solution treating hypertension, in Japan from September 1, 2022. Looking ahead, the app will be prescribed and provided to patients with hypertension as a health insurance treatment at medical institutions.

PRODUCT

#reimbursement

#mobile app

#pdt

View Analyst & Ambassador Comments
Go to original news
Jul 28,2021

Withings and One Drop Partner to Bring Best-In-Class Medical Devices to Multi-Condition Employer Program

Withings, early pioneers of the connected health revolution, and One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, are partnering to connect One Drop’s predictive health platform with Withings’ best-in-class smart medical devices for blood pressure and weight management. Together, the companies will bring connected health solutions to employers, empowering workforces worldwide to make more informed decisions and live healthier lives.

COLLABORATION PARTNERSHIP

#connected device

#rpm

View Analyst & Ambassador Comments
Go to original news
Aug 06,2021

Study: Adults Over 65 Years More Engaged with Digital Coaching Platform Than Younger Adults

Lark Health, a healthcare company that helps people prevent and manage chronic conditions through an AI-powered platform, today announced results from its latest study, which examined the engagement of adults 65 years and older with a digital health platform compared to that of adults aged 35 to 64 years. The research was published in the peer-reviewed journal Frontiers in Digital Health.

CLINICAL STUDY

#coaching

#telehealth

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 25,2021

Better Therapeutics Secures a Loan Facility Up to $50 million from Hercules Capital

Better Therapeutics has secured a loan facility for up to $50 million from Hercules Capital. The company, a prescription digital therapeutics platform that provides cognitive behavioral therapy to address diabetes, hypertension and other cardiometabolic diseases, announced earlier this year it planned to go public by merging with a special purpose acquisition company.

FUNDING DEBT FINANCE
View Analyst & Ambassador Comments
Go to original news
Sep 09,2021

DarioHealth Chosen by Northeast Regional Employer

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has entered into an agreement to provide its suite of digital therapeutics for diabetes, hypertension and pre-diabetes to a Northeast regional employer ("Employer"). The contract is expected to contribute revenue beginning in the first quarter of 2022. The Employer chose Dario to provide whole health support for the frequently co-occurring conditions of diabetes and hypertension, with one integrated approach.

PRODUCT

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Sep 13,2021

CureApp Hypertension Therapeutics App: Clinical Trial Results Announced at ESC Congress 2021 and Published in the European Heart Journal

This clinical trial ran from January 2020 to December 2020 evaluating the efficacy and safety of the CureApp, therapeutic app for patients with essential hypertension, and represented the world’s first trial of a therapeutic app for the purpose of regulatory approval in the field of hypertension. It was performed as a comparative study of two groups, a control group who received guidance on lifestyle changes based on the Guidelines for the Management of Hypertension 2019, and an intervention group who used this therapeutic app in addition to applying lifestyle changes in accordance with said Guidelines.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 15,2021

New LifeScan and Welldoc Partnership Brings Consumers an Evidence-Based Approach to Managing Diabetes and Other Chronic Conditions

LifeScan, the maker of the iconic OneTouch® brand products, and Welldoc, a digital health leader revolutionizing chronic care, today announced a strategic partnership to incorporate Welldoc’s chronic condition platform, supporting hypertension, heart failure, diabetes, pre-diabetes and behavioral health, into the new OneTouch® Solutions portal, designed to offer a choice of support, guidance and digital tools to help people not just manage diabetes but thrive. OneTouch Solutions will be offered to consumers in the US starting this fall, and then offered to healthcare providers and payors as a reimbursed adjudicated option in early 2022.

COLLABORATION PARTNERSHIP

#product & service

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 19,2021

CureApp and Jichi Medical University collaborate on a hypertension therapeutics app Primary endpoint met in Phase III clinical trial in Japan

CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake; hereafter “the Company”) has completed a Japanese Phase III multicenter randomized controlled trial of their digital therapeutics (“DTx”) app to treat hypertension, which was jointly researched by a team led by Professor Kazuomi Kario at Jichi Medical University. Results of this study showed a statistically significant difference in average systolic blood pressure*1 over a 24-hour period - the primary endpoint of this study, demonstrating a hypotensive effect.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 26,2021

One Drop Receives CE Mark, Launches Data-Driven Insights for People Managing High Blood Pressure

One Drop, a leader in precision health solutions for people living with chronic conditions, today announced it has received the Conformité Européenne (CE) Mark for its Blood Pressure Trend and Analysis Engine-1 to generate blood pressure (BP) insights. As part of the One Drop Digital Membership, consumer and employer members worldwide can now receive in-app messages with blood pressure trends, behavioral reinforcements, and alerts for hypertensive crises.

REGULATORY CE MARK

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Subscribe to HYPERTENSION